PetVivo Holdings, Inc.
PetVivo Holdings, Inc. is a U.S.-based animal health company focused on veterinary medical devices and therapeutics. Its core commercial product is Spryng®, which is sold to veterinarians and distributed through animal-health wholesalers and distribution partners.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaSales of the company's lead veterinary medical device used in animal care settings.
Sales made directly to veterinarians through the company's own sales efforts.
Sales routed through animal-health distribution partners such as MWI, Covetrus, Vedco, and Clipper.
Asiakkaat
PetVivo sells primarily into the veterinary market, where veterinarians buy Spryng® for use in animal treatment settings. A meaningful portion of sales also flows through animal-health distributors and wholesalers that serve veterinary clinics and practices. The business depends on both end-customer adoption by veterinarians and the ability of distribution partners to place product efficiently.
Buy Spryng® directly for use in treating animal patients and for clinic inventory.
Purchase and resell Spryng® to veterinary customers through established distribution networks.
Use or stock the product as part of routine animal care and treatment workflows.
Influence demand indirectly through willingness to pursue veterinarian-recommended treatments.
Strategia
PetVivo’s strategy is to expand commercialization of Spryng® through a mix of direct sales and third-party distribution. The company is also focused on building brand awareness and product promotion in the veterinary market to increase adoption and market penetration.
Revenue growth depends on broader veterinarian adoption and stronger channel execution.
Third-party distributors extend market reach and are important to product placement.
Awareness and promotion are necessary to drive veterinarian demand in a competitive market.
Maantiede
PetVivo is headquartered in the United States and its commercial activity is centered on the U.S. veterinary market. The company’s reported distribution relationships and direct sales efforts are focused on U.S. veterinarians, making domestic adoption the key geography for revenue generation. No country-level revenue breakdown was disclosed in the provided excerpts.
Riskit
PetVivo faces execution risk because its business depends on building a sales force, managing distributors, and converting veterinarians into repeat customers. It also operates in a highly competitive animal-health market where larger companies have greater resources, and its small scale increases sensitivity to channel loss, brand weakness, and financing constraints.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has disclosed substantial doubt about its ability to continue as a going concern, making access to capital critical.
Kohdistuu: Equity financing and operating runway
- Dependence on Spryng® commercializationVaikutus: KorkeaTodennäköisyys: Korkea
The company’s revenue base is concentrated in a single lead product, so weak adoption would directly limit growth.
Kohdistuu: Spryng®
- Loss or disruption of distribution agreementsVaikutus: KorkeaTodennäköisyys: Korkea
A large share of revenue is generated through distributors, so partner changes can quickly affect sales reach.
Kohdistuu - Nasdaq delisting / OTCQB trading statusVaikutus: KorkeaTodennäköisyys: Korkea
Loss of a senior exchange listing can reduce liquidity, investor access, and financing flexibility.
Kohdistuu: Public market access
- Competition from larger animal-health companiesVaikutus: KeskitasoTodennäköisyys: Korkea
Competitors have greater financial, technical, and commercial resources and established brands.
Kohdistuu: Veterinary therapeutics and devices
Kirjanpito
Harkinnanvaraiset erätSubstantial doubt about continuation requires investors to assess financing needs and survival risk.
Vaikutus: Affects audit opinion, disclosure, and valuation assumptions
Shares issued to employees, board members, and consultants create non-cash expense and dilution.
Vaikutus: Impacts operating expenses and share count
Equity-linked instruments can change capital structure and require valuation and classification analysis.
Vaikutus: Affects equity, dilution, and potentially fair value measurements
Issuing shares for services requires fair value measurement of compensation expense.
Vaikutus: Affects SG&A and equity balances
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Petco Health & Wellness Company, Inc.
WOOF · Retail-Retail Stores, NEC
enVVeno Medical Corp
NVNO · Surgical & Medical Instruments & Apparatus
enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency.
Phibro Animal Health Corporation
PAHC · Pharmaceutical Preparations
Pharma-Bio Serv, Inc.
PBSV · Services-Management Consulting Services
Elanco Animal Health Inc
ELAN · Pharmaceutical Preparations
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Päivitetty: 24.9.2026